#Inclisiran
LightNews LightNews
medchemexpress.bsky.social
🧬Molecule of the Moment | #Leqvio® (#Inclisiran) received #FDA approval for new indication enabling #first-line use, highlighting its role in #cholesterol management.
✨MedChemExpress offers Inclisiran sodium for research use only. familyheart.org/fda-expands-...
#FDAApproval #ASCVD
FDA Expands Approvals For Repatha® and Leqvio® For LDL-Cholesterol Management - Family Heart Foundation
For many individuals and families, managing high LDL-C, often called "bad cholesterol," is a constant challenge. This is especially true for those living with inherited conditions like Familial…
familyheart.org
November 17, 2025 at 5:02 PM
christosargyrop.bsky.social
Btw I am about to start giving inclisiran in our clinics because of stupidities like this
October 10, 2025 at 8:55 PM
jmksnow.bsky.social
usually for PCSK9i have to explicitly document *which* two generic statins and doses

inclisiran for Medicare is much easier since it's paid for with part B
October 10, 2025 at 8:47 PM
christosargyrop.bsky.social
Go-to phrase in anticipation of IV iron in CKD, PCKS9/inclisiran for hyperlipidemia

@mikejohansenmd.medsky.social
October 10, 2025 at 5:45 PM
themedicalletter.bsky.social
It’s Trivia Tuesday! This question is from our article Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction bit.ly/3Kudggb

Answer: d
Diarrhea, bronchitis, and extremity pain have also been reported.
September 30, 2025 at 7:25 PM
pccs.bsky.social
🚀Launching: Leaders in Lipids is live! A free virtual learning series to support lipid optimisation in UK primary care.
🗓 30 Sept @ 10:00–12:45 Webinar 1
Topics include LDL reduction, setting up an inclisiran service + QOF CHOL004 support.
🔗 bit.ly/483ImFs
September 30, 2025 at 12:30 PM
medscapefrancais.bsky.social
Inclisiran : des effets hypocholestérolémiants mais pas que ?
ms.spr.ly/63326sQxHu
Inclisiran : des effets hypocholestérolémiants mais pas que ?
Il est démontré que l’inclisiran, un petit ARN interférent anti- PCSK9, administré deux fois par an, réduit fortement le LDL cholestérol. Il s’agit donc d’une option thérapeutique potentiellement utile pour les patients à risque cardiovasculaire. Mais son action passe-t-elle uniquement par une réduction du LDL C ?
ms.spr.ly
September 30, 2025 at 11:31 AM
whatsupdoc-lemag.bsky.social
Hypercholestérolémie : inclisiran s’affirme comme alternative crédible aux statines
➡️ https://l.whatsupdoc-lemag.fr/Wwm
September 15, 2025 at 1:32 PM
themedicalletter.bsky.social
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction bit.ly/4gfaCHb
September 9, 2025 at 6:43 PM
accintouch.bsky.social
An inclisiran-based treatment strategy for patients with hypercholesterolemia at high risk for #CVD events helped achieve individual LDL-C goals compared with placebo, based on findings from VICTORION-Difference presented at #ESCCongress. Details: https://bit.ly/463MS43
August 30, 2025 at 8:14 PM
herzmedizin.bsky.social
✨ #ESCCongress 2025: #Inclisiran (PCSK9-siRNA) senkt LDL-C stärker & ist verträglicher als Standard-Therapie – 📊 Ergebnisse der Phase-4-Studie (VICTORION-Difference) mit 1.776 Patienten vorgestellt von Prof. U. Landmesser & kommentiert von Prof. U. Laufs.
➡️ herzmedizin.de/fuer-...
#CardioSky
Inclisiran wirksamer und verträglicher als Standard-Therapie
ESC 2025 | VICTORION-Difference: Vorteile für Inclisiran vs. Placebo bei Hypercholesterinämie und hohem kardiovaskulärem Risiko. Von Prof. U. Laufs.
herzmedizin.de
August 30, 2025 at 3:08 PM
skipbidder.bsky.social
...
What are we learning about?
CETP inhibitors
PCSK9 inhibitors
Bempedoic acid
Pelacarsen
Inclisiran

Okay.
Whatever. You are just making up names now.
Maybe I'll try to stretch out that early VA pension until I can get the 401K.

(2/2)
August 27, 2025 at 6:36 AM
tctmd.bsky.social
Inclisiran may now be used as a stand-alone treatment to reduce LDL cholesterol and may also be an option for those who are unwilling or unable to tolerate statins, according to an announcement from Novartis. www.tctmd.com/news/inclisi...
Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol
The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
www.tctmd.com
August 14, 2025 at 3:17 PM
tctmd.bsky.social
Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol
Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol
Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol cmacahilig@crf.org Wed, 08/06/2025 - 15:50 Michael O'Riordan The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
www.tctmd.com
August 6, 2025 at 7:59 PM
whatsupdoc-lemag.bsky.social
Chez des patients sans traitement antécédent, sans diabète ni antécédent d’ASCVD, inclisiran en monothérapie abaisse le LDL-C de près de 50% en six mois. Cette étude encourage le développement de nouvelles stratégies de réduction lipidique sans statine.
➡️ https://l.whatsupdoc-lemag.fr/YkK
August 2, 2025 at 7:30 AM
hmkyale.bsky.social
“CV Prevention is in reach but only w/ implementation that’s global, upstream, and grounded in data.”
In this week’s #JACCThisWeek, I highlight Focus Issue on Prevention: polypills, syndemics, PREVENT, inclisiran, and more. @jaccjournals.bsky.social
🎧 Listen here: www.jacc.org/digital-cont...
Podcast Episode: Prevention in Focus: Polypill Projections, Risk Equations & Global Syndemic Trends | JACC This Week
In this special prevention-focused issue of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz spotlights new research that underscores the urgent global need to prevent cardiovascular disease. From ...
www.jacc.org
July 17, 2025 at 3:21 PM
medscape.com
A 6-month study finds monotherapy with the injected agent inclisiran is effective and safe in reducing LDL levels in patients at a low-to-borderline risk for atherosclerotic cardiovascular disease.
http://ms.spr.ly/63328SLSLp
Cholesterol
June 29, 2025 at 10:00 PM
springermedicine.com
#MedNews - Treatment with #inclisiran, a PCSK9 protein blocker, significantly reduces low-density lipoprotein cholesterol in adults at low risk for #ASCVD.

Full story 👉 buff.ly/p4S9fcn

#CardioTwitter
Inclisiran monotherapy significantly reduces LDL-C in patients at low ASCVD risk
Treatment with inclisiran, a PCSK9 protein blocker, significantly reduces low-density lipoprotein cholesterol in adults at low risk for atherosclerotic cardiovascular disease.
springermedicine.com
June 24, 2025 at 10:54 AM
pharmrj.pharmsky.app
Inclisiran adoption?
June 18, 2025 at 6:25 PM
tctmd.bsky.social
Data from the VICTORION-INCEPTION study revealed that more patients treated with inclisiran, along with statin and nonstatin lipid-lowering therapies, achieved LDL-cholesterol targets than with usual care alone. Read it all here: www.tctmd.com/news/inclisi...
Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION
(UPDATED) Nearly two-thirds of patients reached < 70 mg/dL with the small interfering RNA therapy.
www.tctmd.com
June 13, 2025 at 3:51 PM
tctmd.bsky.social
Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION
Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION
Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION cmacahilig@crf.org Wed, 06/04/2025 - 14:12 Michael O'Riordan Nearly two-thirds of patients reached < 70 mg/dL with the small interfering RNA therapy.
www.tctmd.com
June 4, 2025 at 6:26 PM
tctmd.bsky.social
Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention
Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention
Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention sciprian@crf.org Wed, 05/07/2025 - 16:49 Michael O'Riordan With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.
www.tctmd.com
May 7, 2025 at 8:59 PM
nixassedes.bsky.social
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial🔓
www.sciencedirect.com/science/arti...
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial
Inclisiran administration twice-yearly (after initial and 3-month doses) effectively reduces low-density lipoprotein cholesterol (LDL-C) in patients o…
www.sciencedirect.com
May 5, 2025 at 1:55 PM
realbiomassspec.bsky.social
Comparative Metabolism of a GalNAc-Conjugated siRNA, Inclisiran, Among Various In Vitro Systems and Correlations with In Vivo Metabolism in Rats #DMD #MassSpec dmd.aspetjournals.org/article/S009...
Comparative Metabolism of a GalNAc-Conjugated siRNA, Inclisiran, Among Various In Vitro Systems and Correlations with In Vivo Metabolism in Rats
GalNAc-conjugated small interfering RNAs (siRNAs) have emerged as a promising new class of therapeutics, demonstrating potential across various disease areas. Metabolic stability is a critical factor ...
dmd.aspetjournals.org
April 30, 2025 at 6:34 PM
dlbhattmd.bsky.social
Potential impact of the ongoing VICTORION-1 PREVENT trial - bottom line, millions of patients could be eligible for therapy with inclisiran. #CardioSky #MedSky #Cardiology #Cardiovascular #Prevention @ajpcardio.bsky.social
ajpcardio.bsky.social American Journal of Preventive Cardiology @ajpcardio.bsky.social · Apr 25
>23 million US adults meet criteria for the ongoing trial of inclisiran for primary prevention (VICTORION-1 Prevent), yet rates of lipid-lowering therapy use are low among this high-risk population.

www.sciencedirect.com/science/arti...

#CardioSky #MedSky
April 27, 2025 at 4:37 PM